ArticleCureus2025
Assessment of Disease Burden Among Japanese Patients With Pulmonary Sarcoidosis: A Questionnaire-Based Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSarcoidosis is a systemic granulomatous disease that can form lesions in almost all organs and most commonly affects the lung. It often causes systemic symptoms such as generalized pain and fatigue, leading to reduced health-related quality of life (HRQoL). Although oral corticosteroids (OCS) are commonly used to manage sarcoidosis, they are associated with side effects and reduced HRQoL. In Japan, data on patient-reported outcomes remain limited.
methodsThis study assessed the disease burden in 158 Japanese patients with pulmonary sarcoidosis, recruited through a sarcoidosis patients' association, using a mailed questionnaire that included three patient-reported outcome measures: the King's Sarcoidosis Questionnaire (KSQ), Fatigue Assessment Scale (FAS), and Small Fiber Neuropathy Screening List (SFNSL).
resultsThe mean age of patients was 68.4 years, and 85.4% were women. The median KSQ General Health Status score was 54.3, indicating a reduced HRQoL. Fatigue was prevalent, with 72.3% of patients scoring ≥22 on the FAS. Small fiber neuropathy (SFN) was suspected in 79.7% of patients with SFNSL scores ≥11. Patients receiving higher doses of OCS (n = 40) had significantly lower KSQ medication scores compared with those receiving lower doses of OCS (median 61.7 vs. 80.9, p = 0.001), suggesting a higher treatment burden. Additionally, OCS users exhibited a higher prevalence of extreme fatigue (FAS ≥35, 26% vs. 14%, p = 0.030) and suspected SFN (SFNSL ≥11, 90% vs. 70%, p < 0.001).
conclusionThese findings quantitatively demonstrate the burden of systemic symptoms, particularly fatigue and symptoms associated with SFN, in Japanese patients with pulmonary sarcoidosis, with the present study being the first to evaluate KSQ scores in Japan. Even though this study could not establish causality due to its cross-sectional nature, the results underscore the importance of regularly monitoring and managing fatigue and symptoms associated with SFN in patients undergoing treatment with OCS. Such insights may support clinical decision-making and could contribute to optimizing management while minimizing HRQoL impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.